FTC Seeks Appeals Court Rehearing Of Zoloft Declaratory Judgment Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal Circuit panel's decision requiring Teva to establish a "reasonable apprehension" of being sued by Pfizer ignores Waxman/Hatch's recognition that generic firms may overcome ANDA approval "bottlenecks" by obtaining a court decision, Federal Trade Commission says in an amicus brief.